

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWEILL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 28 AUGUST 2026 AND RETIREMENT OF DIRECTOR

References are made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of annual general meeting (the “**AGM**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) dated 31 July 2026.

POLL RESULTS OF THE AGM

The board of directors (the “**Board**”) of the Company announces that all the proposed resolutions (the “**Resolutions**”) as set out in the Notice were duly passed by the shareholders of the Company (the “**Shareholders**”) by way of poll as ordinary resolutions at the AGM held on 28 August 2026.

As at the date of the AGM, the total number of issued shares of the Company (the “**Shares**”) was 2,900,000,000 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the Resolutions at the AGM pursuant to Rule 13.40 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). No Shareholder was required under the Listing Rules to abstain from voting at the AGM.

Tricor Investor Services Limited, the Company’s Hong Kong branch share registrar and transfer office, acted as the scrutineer for the vote-taking at the AGM.

The poll results in respect of the Resolutions at the AGM are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited financial statements and the reports of the directors and the auditor of the Company for the year ended 31 March 2026.	919,330,540 (100%)	0 (0%)
2.	(a) To re-elect Dr. Guo Yi as executive director.	919,330,540 (100%)	0 (0%)
	(b) To re-elect Ms. Yang Xiaorong as independent non-executive director.	919,330,540 (100%)	0 (0%)
	(c) To authorise the board of directors of the Company to fix the directors' remuneration.	919,330,540 (100%)	0 (0%)
3.	To re-appoint the Company's auditor and authorise the board of directors of the Company to fix its remuneration.	919,330,540 (100%)	0 (0%)
4.	To grant a general mandate to the directors of the Company to allot, issue and otherwise deal with the Company's shares.	919,330,540 (100%)	0 (0%)
5.	To grant a general mandate to the directors of the Company to buy back the Company's shares.	919,330,540 (100%)	0 (0%)
6.	To extend the general mandate granted to the directors of the Company to allot, issue and deal with the Company's shares by the addition thereto the total number of shares bought back by the Company.	919,330,540 (100%)	0 (0%)

The full text of the Resolutions is set out in the Notice.

As more than 50% of the votes were cast in favour of each of the Resolutions numbered 1 to 6 above, these Resolutions were duly passed as ordinary resolutions of the Company.

The Company's directors, Dr. Guo Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen, Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong attended the AGM in person, and Dr. Xie Yi attended the AGM by electronic means.

RETIREMENT OF DIRECTOR

As disclosed in the Circular, Dr. Lou Yi (“**Dr. Lou**”) would retire as an executive Director by rotation in accordance with the bye-laws of the Company at the AGM and Dr. Lou indicated that he would not offer himself for re-election at the AGM due to age and health considerations. Accordingly, with effect from the conclusion of the AGM, Dr. Lou retired as an executive Director (the “**Retirement**”). Dr. Lou will remain as a director of certain subsidiaries of the Company following his Retirement.

Dr. Lou has confirmed that he has no disagreement with the Board, and there is no other matter in relation to his Retirement that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Lou for his valuable contribution to the Company during his tenure of office as an executive Director.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 28 August 2026

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong and Ms. Wong Sau Kuen, and the independent non-executive directors are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.

** For identification purpose only*